A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

BACKGROUND: Long-acting muscarinic antagonist (LAMA) and long-acting β(2)-agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). This Phase IIb study investigated the safety and efficacy of four doses of the LAMA glycopyrronium (GP) del...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerwin, Edward M., Spangenthal, Selwyn, Kollar, Christine, St Rose, Earl, Reisner, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838878/
https://www.ncbi.nlm.nih.gov/pubmed/29506504
http://dx.doi.org/10.1186/s12931-018-0739-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838878/
https://www.ncbi.nlm.nih.gov/pubmed/29506504
http://dx.doi.org/10.1186/s12931-018-0739-6

Ejemplares similares